We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+12.51%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$2.72B
AUM Growth
+$313M
Cap. Flow
+$128M
Cap. Flow %
4.71%
Top 10 Hldgs %
27.21%
Holding
156
New
12
Increased
32
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
SEND
SendGrid, Inc.
SEND
+$62.1M
2
ALTR
Altair Engineering Inc
ALTR
+$38.1M
3
ZGNX
Zogenix, Inc.
ZGNX
+$35.9M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$33.5M
5
ARGX icon
argenx
ARGX
+$20.8M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$42M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$29.8M
3
W icon
Wayfair
W
+$28.7M
4
IDTI
Integrated Device Technology I
IDTI
+$26.3M
5
ELLI
Ellie Mae Inc
ELLI
+$25.1M

Sector Composition

Rank Sector Weight
1 Healthcare 45.7%
2 Technology 19.3%
3 Consumer Discretionary 10.25%
4 Industrials 6.97%
5 Communication Services 2.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
76
DELISTED
Exact Sciences
EXAS
$10.3M 0.38%
131,000
– –
RCKT icon
77
Rocket Pharmaceuticals
RCKT
$351M
$9.71M 0.36%
394,585
– –
IFRX icon
78
InflaRx
IFRX
$253M
$9.44M 0.35%
275,000
– –
REGN icon
79
Regeneron Pharmaceuticals
REGN
$77.4B
$9.29M 0.34%
23,000
– –
XNCR icon
80
Xencor
XNCR
$1.59B
$8.88M 0.33%
228,000
– –
GBT
81
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8.74M 0.32%
+230,000
New +$10.2M
WVE icon
82
Wave Life Sciences
WVE
$1.11B
$8.52M 0.31%
170,400
-156,000
-48% -$7.04M
FOLD
83
DELISTED
Amicus Therapeutics
FOLD
$8.46M 0.31%
+700,000
New +$9.79M
ETTX
84
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$8.14M 0.3%
+772,556
New +$8.12M
KNSA icon
85
Kiniksa Pharmaceuticals
KNSA
$6.1B
$8.13M 0.3%
319,000
+22,600
+8% +$439K
BCRX icon
86
BioCryst Pharmaceuticals
BCRX
$2.35B
$7.99M 0.29%
+1,047,000
New +$7.03M
INCY icon
87
Incyte
INCY
$24.9B
$7.94M 0.29%
115,000
– –
XLRN
88
DELISTED
Acceleron Pharma
XLRN
$7.38M 0.27%
128,900
-401,000
-76% -$19.7M
UROV
89
DELISTED
Urovant Sciences Ltd.
UROV
$7.14M 0.26%
+594,816
New +$7.03M
MDGL icon
90
Madrigal Pharmaceuticals
MDGL
$11.4B
$7.07M 0.26%
33,000
-13,000
-28% -$3.26M
RARX
91
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$7.02M 0.26%
388,000
– –
CERN
92
DELISTED
Cerner Corp
CERN
$6.97M 0.26%
108,200
– –
EXR icon
93
Extra Space Storage
EXR
$31.3B
$6.93M 0.25%
80,000
– –
RARE icon
94
Ultragenyx Pharmaceutical
RARE
$2.56B
$6.67M 0.25%
87,400
– –
SUPN icon
95
Supernus Pharmaceuticals
SUPN
$2.65B
$6.55M 0.24%
130,000
– –
RGEN icon
96
Repligen
RGEN
$7.03B
$6.1M 0.22%
110,000
– –
FENC icon
97
Fennec Pharmaceuticals
FENC
$344M
$6.08M 0.22%
741,175
– –
AGIO icon
98
Agios Pharmaceuticals
AGIO
$1.95B
$5.78M 0.21%
75,000
-103,000
-58% -$8.29M
ALNY icon
99
Alnylam Pharmaceuticals
ALNY
$27.4B
$5.43M 0.2%
62,000
– –
VIRX
100
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.53M 0.17%
64,727
– –
2 3
4
5 6

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2018 Portfolio in Review

As of Q3 2018, Eventide Asset Management held 156 positions worth $2.72B, up 13% from $2.41B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Eventide Asset Management deployed $128M of net new capital in Q3 2018, opening 12 new positions and adding to 32 existing holdings. Its largest new stake was SendGrid, Inc.: 1,968,653 shares worth $72.4M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 42% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was AbbVie, an estimated $42M trimmed.

  • Eventide Asset Management's largest Q3 2018 buy was SendGrid, Inc.: 1,968,653 shares worth $72.4M.
  • Eventide Asset Management added most to Zogenix, Inc. in Q3 2018, an estimated $35.9M increase.
  • Eventide Asset Management's biggest Q3 2018 reduction was AbbVie, cutting an estimated $42M.
  • Eventide Asset Management fully exited Integrated Device Technology I in Q3 2018, selling an estimated $26.3M.
  • Eventide Asset Management's ten largest holdings make up 27% of its $2.72B portfolio in Q3 2018.
  • Eventide Asset Management opened 12 new positions and closed 11 in Q3 2018.
  • Eventide Asset Management's portfolio value rose 13% quarter-over-quarter to $2.72B.

Based on Eventide Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.